Transcriptomic and Quantitative Proteomic Analysis of Transporters and Drug Metabolizing Enzymes in Freshly Isolated Human Brain Microvessels
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
We have investigated the transcriptomic and/or proteomic patterns of 71 solute carrier (SLC) and organic solute (OST) transporters, 34 ATP-binding cassette (ABC) transporters, and 51 metabolizing enzymes in human brain microvessels. We used quantitative RT-PCR and LC-MS/MS to examine isolated brain microvessels and cortex biopsies from 12 patients with epilepsia or glioma. SLC2A1/GLUT1, SLC1A3/EAAT1, and SLC1A2/EAAT2 were the main SLC proteins whereas ABCG2/BCRP, ABCB1/MDR1, ABCA2 and ABCA8 were the main ABC quantified in isolated brain microvessels; ABCG2/BCRP was 1.6-fold more expressed than ABCB1/MDR1, and ABCC4/MRP4 was 10 times less abundant than ABCB1/MDR1. CYP1B1 and CYP2U1 were the only quantifiable CYPs. Finally, GSTP1, COMT, GSTM3, GSTO1 and GSTM2 proteins were the main phase II enzymes quantified; UGTs and NATs were not detected. Our extensive investigation of gene and protein patterns of transporters and metabolizing enzymes provides new molecular information for understanding drug entry and metabolism in the human blood-brain barrier.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most efforts to combine transcriptomic and proteomic profiling have compared or validated the expression of genes via the abundance of their RNAs and proteins, including characterisation of abundance across healthy tissues45, changes due to neurological disorders46, and localised expression in neuronal processes47.”
From Decoding neuroproteomics: integrating the genome, translatome and functional anatomy (2014) · cites this paper as [46]
Citations
Cites
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Chen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675
Induction of phase I, II and III drug metabolism/transport by xenobiotics
Xu, C., Li, C. Y.-T., & Kong, A.-N. T. (2005) · Archives of Pharmacal Research · doi:10.1007/bf02977789 · Cited by 1,279
Hediger, M. A., Romero, M. F., Peng, J.-B., Rolfs, A., Takanaga, H., & Bruford, E. A. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1192-y · Cited by 985
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
Self-citationBlood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
Kamiie, J., Ohtsuki, S., Iwase, R., Ohmine, K., Katsukura, Y., Yanai, K., Sekine, Y., Uchida, Y., Ito, S., & Terasaki, T. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9532-4 · Cited by 478
Self-citationTransporting therapeutics across the blood-brain barrier
Abbott, N. J., & Romero, I. A. (1996) · Molecular Medicine Today · doi:10.1016/1357-4310(96)88720-x · Cited by 447
Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2)
Lee, W., Glaeser, H., Smith, L. H., Roberts, R. L., Moeckel, G. W., Gervasini, G., Leake, B. F., & Kim, R. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411092200 · Cited by 365
Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human
Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060194 · Cited by 351
Research works printed but not linked: 3
- Hagenbuch B., 2002, News Physiol. Sci., 17, 231
- Martinasevic M. K., 1998, Drug Metab. Dispos., 26, 1039
- Cornford E. M., 1992, Cancer Res., 52, 138
Cited by
Development, maintenance and disruption of the blood-brain barrier
Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3407 · Cited by 2,452
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
“For instance, CYP2U1 metabolizes fatty acids like arachidonic CYP1B1 has a role in the metabolism of endogenous compounds in the CNS [19].”
BackgroundBlood–brain barrier structure and function and the challenges for CNS drug delivery
Abbott, N. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9608-0 · Cited by 909
Helms, H. C., Abbott, N. J., Burek, M., Cecchelli, R., Couraud, P.-O., Deli, M. A., Förster, C., Galla, H. J., Romero, I. A., Shusta, E. V., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16630991 · Cited by 843
Self-citationThe blood–brain barrier in health and disease
Daneman, R. (2012) · Annals of Neurology · doi:10.1002/ana.23648 · Cited by 754
Park, T.-E., Mustafaoglu, N., Herland, A., Hasselkus, R., Mannix, R., FitzGerald, E. A., Prantil-Baun, R., Watters, A., Henry, O., Benz, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10588-0 · Cited by 594
Ohtsuki, S., Schaefer, O., Kawakami, H., Inoue, T., Liehner, S., Saito, A., Ishiguro, N., Kishimoto, W., Ludwig-Schwellinger, E., Ebner, T., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042259 · Cited by 434
“Quantification of human transporters and other membrane proteins was based on the MRM conditions reported previously (Kamiie et al., 2008; Ohtsuki et al., 2011; Sakamoto et al., 2011; Shawahna et al., 2011; Uchida et al., 2011).”
MethodSelf-citationDando, S. J., Mackay-Sim, A., Norton, R., Currie, B. J., St. John, J. A., Ekberg, J. A. K., Batzloff, M., Ulett, G. C., & Beacham, I. R. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00118-13 · Cited by 428
“carrier transporters, which are expressed on cerebral microvessels (75, 77-79).”
BackgroundRole of Monocarboxylate Transporters in Drug Delivery to the Brain
Vijay, N., & Morris, M. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990462 · Cited by 408
“The results of this study demonstrated the expression of MCT1 in these samples [81].”
ResultBlood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
Erickson, M. A., & Banks, W. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014647 · Cited by 378
“Glutathione S-transferases are also expressed in human brain capillaries (Shawahna et al., 2011).”
BackgroundOverview and introduction: The blood–brain barrier in health and disease
Abbott, N. J., & Friedman, A. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03696.x · Cited by 362
“…(ABCB1) and/or BCRP (ABCG2) are the dominant players on the apical (blood-facing) membrane, especially Pgp in rodents and BCRP in primates, but the expression levels, localization, and roles of the multidrug-resistant associated proteins (MRPs, ABCC group) are less clear (Shawahna et al., 2011).”
BackgroundRenal Transporters in Drug Development
Morrissey, K. M., Stocker, S. L., Wittwer, M. B., Xu, L., & Giacomini, K. M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140317 · Cited by 324
Polyphenols journey through blood-brain barrier towards neuronal protection
Figueira, I., Garcia, G., Pimpão, R. C., Terrasso, A. P., Costa, I., Almeida, A. F., Tavares, L., Pais, T. F., Pinto, P., Ventura, M. R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11512-6 · Cited by 290
The role of glucose transporters in brain disease: Diabetes and Alzheimer’s disease
Shah, K., DeSilva, S., & Abbruscato, T. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012629 · Cited by 288
“cells with lower levels of GLUT3 [47–51], GLUT4 [52] SGLT1 [53] and SGLT2 [50] compared to GLUT1 protein levels in human as well as other species.”
BackgroundStrazielle, N., & Ghersi-Egea, J. F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300518e · Cited by 263
Heterogeneity of the blood-brain barrier
Wilhelm, I., Nyúl-Tóth, Á., Suciu, M., Hermenean, A., & Krizbai, I. A. (2016) · Tissue Barriers · doi:10.1080/21688370.2016.1143544 · Cited by 247
“In human brain microvessels the most abundantly expressed ABC transporters are ABCG2/BCRP, ABCB1/MDR1, ABCC1, ABCC4, ABCC5, ABCA2 and ABCA8, while the main SLC transporters are SLC2A1/GLUT1, SLC7A5/LAT1, SLC16A1/ MCT1, SLC1A3/EAAT1 and SLC1A2/EAAT2.”
BackgroundIn Vitro Models of the Blood-Brain Barrier
Neuhaus, W. (2020) · Handbook of Experimental Pharmacology · doi:10.1007/164_2020_370 · Cited by 236
Molecular mechanisms of brain water transport
MacAulay, N. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00454-8 · Cited by 231
Ohtsuki, S., Ikeda, C., Uchida, Y., Sakamoto, Y., Miller, F., Glacial, F., Decleves, X., Scherrmann, J.-M., Couraud, P.-O., Kubo, Y., et al. (2013) · Molecular Pharmaceutics · doi:10.1021/mp3004308 · Cited by 230
Self-citationUchida, Y., Tachikawa, M., Obuchi, W., Hoshi, Y., Tomioka, Y., Ohtsuki, S., & Terasaki, T. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-21 · Cited by 221
“We successfully quantified more than 100 transporter proteins in isolated human brain microvessels [6,19].”
Self-citationIn Vitro Models of the Blood–Brain Barrier for the Study of Drug Delivery to the Brain
Wilhelm, I., & Krizbai, I. A. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500046f · Cited by 211
Hladky, S. B., & Barrand, M. A. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0113-6 · Cited by 206
Role of the Blood–Brain Barrier in the Nutrition of the Central Nervous System
Campos-Bedolla, P., Walter, F. R., Veszelka, S., & Deli, M. A. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.11.018 · Cited by 197
“Receptor-mediated transport Peptides, proteins at the BBB (1,4,13).”
InfluentialKalvass, J. C., Polli, J. W., Bourdet, D. L., Feng, B., Huang, S.-M., Liu, X., Smith, Q. R., Zhang, L. K., & Zamek-Gliszczynski, M. J. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.34 · Cited by 197
Rojas-Gutierrez, E., Muñoz-Arenas, G., Treviño, S., Espinosa, B., Chavez, R., Rojas, K., Flores, G., Díaz, A., & Guevara, J. (2017) · Synapse · doi:10.1002/syn.21990 · Cited by 192
“GLUT3 is thus a transporter with an important function in the neuropil, including both dendrites and axons (Mantych, James, Chung, & Devaskar, 1992; Simpson et al., 2008).”
InfluentialPatel, J. P., & Frey, B. N. (2015) · Neural Plasticity · doi:10.1155/2015/708306 · Cited by 177
Efflux transporters in blood-brain interfaces of the developing brain
Strazielle, N., & Ghersi-Egea, J.-F. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00021 · Cited by 157
“REVIEW ARTICLE published: 05 February 2015 doi: 10.3389/fnins.2015.00021”
BackgroundInfluentialMorris, M. E., Rodriguez-Cruz, V., & Felmlee, M. A. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0110-8 · Cited by 174
“31 fmol/μg protein) (19,20), but was not determined in brain capillaries from other species that have been studied using quantitative proteomics.”
BackgroundInfluentialBlood-Brain Barrier Protection as a Therapeutic Strategy for Acute Ischemic Stroke
Sifat, A. E., Vaidya, B., & Abbruscato, T. J. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0091-7 · Cited by 171
Stem Cell-Based Human Blood–Brain Barrier Models for Drug Discovery and Delivery
Aday, S., Cecchelli, R., Hallier-Vanuxeem, D., Dehouck, M. P., & Ferreira, L. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.01.001 · Cited by 169
“[6].”
BackgroundRae, C. D., & Williams, S. R. (2017) · Analytical Biochemistry · doi:10.1016/j.ab.2016.12.022 · Cited by 164
Review: The blood-brain barrier; protecting the developing fetal brain
Goasdoué, K., Miller, S. M., Colditz, P. B., & Bjorkman, S. T. (2016) · Placenta · doi:10.1016/j.placenta.2016.12.005 · Cited by 174
Regulation of ABC transporters at the blood–brain barrier
Miller, D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.64 · Cited by 137
“Available data indicate that a number of ligand-activated receptors are expressed in brain capillary endothelial cells and intact brain capillaries from humans, pigs, and rodents (Figure 2).(10,20,30) These include PXR, CAR, AhR, peroxisome proliferatoractivated receptor a (PPARa), vitamin D receptor (VDR), and glucoc…”
BackgroundLoryan, I., Reichel, A., Feng, B., Bundgaard, C., Shaffer, C., Kalvass, C., Bednarczyk, D., Morrison, D., Lesuisse, D., Hoppe, E., et al. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03246-6 · Cited by 142
Ribecco-Lutkiewicz, M., Sodja, C., Haukenfrers, J., Haqqani, A. S., Ly, D., Zachar, P., Baumann, E., Ball, M., Huang, J., Rukhlova, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19522-8 · Cited by 148
Central nervous system delivery of molecules across the blood-brain barrier
Gosselet, F., Loiola, R. A., Roig, A., Rosell, A., & Culot, M. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2020.104952 · Cited by 137
Saunders, N. R., Habgood, M. D., Møllgård, K., & Dziegielewska, K. M. (2016) · F1000Research · doi:10.12688/f1000research.7378.1 · Cited by 143
Veszelka, S., Tóth, A., Walter, F. R., Tóth, A. E., Gróf, I., Mészáros, M., Bocsik, A., Hellinger, É., Vastag, M., Rákhely, G., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00166 · Cited by 132
“Pgp and BCRP were identified as the two primary efflux transporters at the BBB in both human (Shawahna et al., 2011; Uchida et al., 2011) and rat brain microvessels (Enerson and Drewes, 2005; Hoshi et al., 2013).”
BackgroundNakamura, K., Hirayama‐Kurogi, M., Ito, S., Kuno, T., Yoneyama, T., Obuchi, W., Terasaki, T., & Ohtsuki, S. (2016) · PROTEOMICS · doi:10.1002/pmic.201500433 · Cited by 136
Self-citationRecent advances in human iPSC-derived models of the blood–brain barrier
Workman, M. J., & Svendsen, C. N. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00191-7 · Cited by 140
Gomez-Zepeda, D., Taghi, M., Scherrmann, J.-M., Decleves, X., & Menet, M.-C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics12010020 · Cited by 124
“(C) Primary or cell lines of brain endothelial cells (EC) can be cultured (a) directly in wells to study drug absorption or (b) in transwells for permeability assays; (c to f) cocultures with other cells from the NVU can improve the BBB phenotype, including the tight junctions (black rhombus ♦); (g and h).”
BackgroundMethodInfluentialSelf-citationTransporters of the blood–brain and blood–CSF interfaces in development and in the adult
Saunders, N. R., Daneman, R., Dzięgielewska, K. M., & Liddelow, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.11.006 · Cited by 145
“Later application of more advanced gene profiling microarray techniques (Enerson and Drewes, 2006; Lyck et al., 2009; Marques et al., 2009; Shawahna et al., 2011) was able to provide the full breadth of transcriptome coverage by high throughput screening, but without comparison to similar…”
BackgroundMethodBlood-brain barrier, cytotoxic chemotherapies and glioblastoma
Dréan, A., Goldwirt, L., Verreault, M., Canney, M. S., Schmitt, C., Guehennec, J., Delattre, J., Carpentier, A. C., & Idbaïh, A. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1202761 · Cited by 130
“abundant transporters of the SLC family [4,8,9].”
Al‐Majdoub, Z. M., Feteisi, H. A., Achour, B., Warwood, S., Neuhoff, S., Rostami‐Hodjegan, A., & Barber, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01189 · Cited by 130
de Lange, E. C. M. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-12 · Cited by 132
“This may occur at the level of the BBB and BCSFB, serving as “enzymatic barriers” to drug influx into brain, and also in the ependymal cells lining the CSF ventricles potentially influencing intracerebral distribution [86-89].”
BackgroundPérez-López, A., Torres‐Suárez, A. I., Martín‐Sabroso, C., & Aparicio-Blanco, J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114816 · Cited by 132
Salman, M. M., Marsh, G. A., Küsters, I., Delincé, M., Caprio, G. D., Upadhyayula, S., de Nola, G., Hunt, R., Ohashi, K. G., Gray, T., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.573775 · Cited by 124
Delsing, L., Dönnes, P., Sánchez, J., Clausen, M., Voulgaris, D., Falk, A., Herland, A., Brolén, G., Zetterberg, H., Hicks, R., et al. (2018) · Stem Cells · doi:10.1002/stem.2908 · Cited by 116
Chaves, C., Remiao, F., Cisternino, S., & Decleves, X. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170504095823 · Cited by 113
“Given the evident expression of this transporter at the choroid plexus [128, 129], but not at the BBB [42, 130, 131], loss of Mrp1 expression in choroid plexus may decrease the efflux of morphine and oxymorphone from the CSF into the bloodstream, enhancing their levels in the brain and thus their analgesic activity.”
Self-citationMembrane Transporters in Drug Development
Keogh, J. P. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-398339-8.00001-x · Cited by 121
Glucose metabolism and AD: evidence for a potential diabetes type 3
González, A., Calfío, C., Churruca, M., & Maccioni, R. B. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00996-8 · Cited by 112
“In regard to the glucose transporters, the GLUT1 transporter is expressed in the endothelial cells of the BBB [91, 92]; GLUT3, on the other hand, is expressed in neurons with high affinity to glucose [93, 94], and GLUT4 is expressed in the BBB of the ventromedial hypothalamus [95] and temporal cortex; therefore, it pa…”
BackgroundUchida, Y., Zhang, Z., Tachikawa, M., & Terasaki, T. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13147 · Cited by 108
“For most peptides, the four SRM/MRM transitions employed were those obtained in previous studies using AB SCIEX triple quadrupole mass spectrometers, 4000QTRAP, API5000 or QTRAP5500 (Kamiie et al. 2008; Ohtsuki et al. 2011; Shawahna et al. 2011; Uchida et al. 2011; Hoshi et al. 2013).”
BackgroundMethodResultInfluentialSelf-citationCytochrome P450 expression and regulation in the brain
Kuban, W., & Daniel, W. A. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1858856 · Cited by 112
“In addition to CYP1B1 transcripts, CYP2U1 was also detected in human brain microvessels (Shawahna et al. 2011).”
BackgroundInfluentialHarwood, M. D., Neuhoff, S., Carlson, G., Warhurst, G., & Rostami‐Hodjegan, A. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1810 · Cited by 114
ABC Transporters and the Alzheimer’s Disease Enigma
Wolf, A., Bauer, B., & Hartz, A. M. S. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00054 · Cited by 103
“This development will raise global AD health care costs to unprecedented dimensions (Brookmeyer et al., 2007; WHO, 2007).”
BackgroundDeo, A. K., Theil, F.-P., & Nicolas, J.-M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300570z · Cited by 104
Blood‐brain barrier development: Systems modeling and predictive toxicology
Saili, K. S., Zurlinden, T. J., Schwab, A. J., Silvin, A., Baker, N. C., Hunter, E. S., Ginhoux, F., & Knudsen, T. B. (2017) · Birth Defects Research · doi:10.1002/bdr2.1180 · Cited by 95
“, glycolysis) (Pardridge, 1983) and xenobiotic metabolism (Shawahna et al., 2011).”
BackgroundInfluentialOuzzine, M., Gulberti, S., Ramalanjaona, N., Magdalou, J., & Fournel‐Gigleux, S. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00349 · Cited by 112
“Similarly, investigation of the expression of UGTs in human brain microvessels did not reveal the presence of UGT1A6 (Shawahna et al., 2011), suggesting that this isoform was not expressed or very weakly expressed in human brain microvessels compared to rat.”
BackgroundLim, S. H., Yee, G. T., & Khang, D. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s450853 · Cited by 106
Bao, X., Wu, J., Xie, Y., Kim, S., Michelhaugh, S., Jiang, J., Mittal, S., Sanai, N., & Li, J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1710 · Cited by 92
“Quantitative targeted proteomics indicated that only ABCC4 was expressed at quantifiable but low levels (< 5% of ABCG2 level) in isolated microvessels of human or rodent brain, while ABCC1, 2, 3, 5, and 6 were undetectable.(12,26,34) Immunofluorescence microscopy analysis of protein expression of ABCC1–ABCC6 in human…”
BackgroundResultTargeting Transporters for Drug Delivery to the Brain: Can We Do Better?
Puris, E., Fricker, G., & Gynther, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03241-x · Cited by 92
“23 (51) ABCB1 (P-gp, MDR1) ATP-binding cassette Luminal Vincristine, quinidine, verapamil 6.”
BackgroundInfluentialLahmann, C., Kramer, H. B., & Ashcroft, F. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134476 · Cited by 92
Kubo, Y., Ohtsuki, S., Uchida, Y., & Terasaki, T. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24398 · Cited by 97
Self-citationExtrahepatic metabolism at the body's internal–external interfaces
Gundert‐Remy, U., Bernauer, U., Blömeke, B., Döring, B., Fabian, E. J., Goebel, C., Hessel‐Pras, S., Jäckh, C., Lampen, A., Oesch, F., et al. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.900565 · Cited by 95
Maiuolo, J., Gliozzi, M., Musolino, V., Scicchitano, M., Carresi, C., Scarano, F., Bosco, F., Nucera, S., Ruga, S., Zito, M. C., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092693 · Cited by 89
“Among them, specialized proteins (SLCs) are able to promote the transport of glutamate, aspartate, GABA, and glycine [90,91].”
The need for mathematical modelling of spatial drug distribution within the brain
Vendel, E., Rottschäfer, V., & de Lange, E. C. M. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0133-x · Cited by 91
Gaohua, L., Neuhoff, S., Johnson, T. N., Rostami-Hodjegan, A., & Jamei, M. (2016) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2016.03.005 · Cited by 78
Neurosteroid Transport in the Brain: Role of ABC and SLC Transporters
Grube, M., Hagen, P., & Jedlitschky, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00354 · Cited by 92
“In human brain microvessels, ABCG2/BCRP transcript (Cooray et al., 2002; Warren et al., 2009) and protein was detected as one of the most abundant ABC transporters (Shawahna et al., 2011).”
BackgroundSandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury
Yang, K., Guo, C., Woodhead, J. L., St. Claire, R. L., Watkins, P. B., Siler, S. Q., Howell, B. A., & Brouwer, K. L. R. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.008 · Cited by 85
Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy
Han, H., Mann, A., Ekstein, D., & Eyal, S. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0096-2 · Cited by 83
“A recent study evaluated the transcriptome of 51 metabolizing enzymes in human brain microvessels isolated from four patients with epilepsy and three with oligodendroglioma and the proteome of additional five patients with epilepsy (36).”
BackgroundShimomura, K., Okura, T., Kato, S., Couraud, P., Scherrmann, J., Terasaki, T., & Deguchi, Y. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-8 · Cited by 83
“These hCMEC/D3 cells retain many of the morphological and functional characteristics of the human BBB in terms of expression of multiple transporters, receptors, tight junction proteins and various ABC transporters, including ABCB1 (MDR1/P-gp), ABCC1 (MRP1), ABCC4 (MRP4), ABCC5 (MRP5), and ABCG2 (BCRP) [2,6,7].”
BackgroundSelf-citationFardel, O., Kolasa, É., & Vée, M. L. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.637918 · Cited by 87
“Apical/luminal transport proteins of brain capillary endothelial cells contributing to the blood--brain barrier include the uptake transporters OATP1A2 and OATP2B1 and the efflux pumps P-gp, BCRP, MRP4 and MRP5, whereas OAT3 has been localized at the basolateral pole (Figure 1) [4,52,53].”
BackgroundBillington, S. F., Salphati, L., Hop, C. E. C. A., Chu, X., Evers, R., Burdette, D., Rowbottom, C., Lai, Y., Xiao, G., Humphreys, W. G., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1373 · Cited by 84
“CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 106 NUMBER 1 | JULY 2019 229 fenestrations, and a low pinocytic activity.2,3 Many lipophilic drugs are also excluded from the brain because they are transported out of the brain by the adenosine triphosphate–binding cassette (ABC) efflux transporters (e.g., P- glycoprotein…”
BackgroundResultInfluentialAge-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier
Erdő, F., & Krajcsi, P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00196 · Cited by 76
Castellino, S., Groseclose, M. R., Sigafoos, J., Wagner, D. S., de Serres, M., Polli, J. W., Romach, E. H., Myer, J. R., & Hamilton, B. (2012) · Chemical Research in Toxicology · doi:10.1021/tx3004196 · Cited by 83
Ochiai, Y., Uchida, Y., Ohtsuki, S., Tachikawa, M., Aizawa, S., & Terasaki, T. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13943 · Cited by 85
“08 fmol/lg protein in human brain capillaries in a previous report (Shawahna et al. 2011), and similar to that of the whole cell fraction of hCMEC/D3 cells (4.”
BackgroundMethodResultSelf-citationRodrigues, D., & Rowland, A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1328 · Cited by 79
Behl, T., Kaur, I., Sehgal, A., Kumar, A., Uddin, M. S., & BUNGAU, S. G. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02211-x · Cited by 84
Brzica, H., Abdullahi, W., Ibbotson, K., & Ronaldson, P. T. (2017) · Journal of Central Nervous System Disease · doi:10.1177/1179573517693802 · Cited by 77
Imaging techniques to study drug transporter function in vivo
Tournier, N., Stieger, B., & Langer, O. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.006 · Cited by 79
“more abundant at the mouse BBB than mBCRP (Shawahna et al., 2011; Uchida et al., 2011).”
BackgroundRole of Hepatic Efflux Transporters in Regulating Systemic and Hepatocyte Exposure to Xenobiotics
Pfeifer, N. D., Hardwick, R. N., & Brouwer, K. L. R. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140021 · Cited by 82
Feteisi, H. A., Al‐Majdoub, Z. M., Achour, B., Couto, N. A. S., Rostami‐Hodjegan, A., & Barber, J. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14446 · Cited by 74
“In contrast, Abcg2 is reported to be more abundant than Abcb1 in human and cynomolgus monkey, which indicates inter-species differences as a result of Abcb1 being encoded by two genes (Abcb1a/b) in rodents compared to only one in humans (Ito et al. 2011; Shawahna et al. 2011; Uchida et al. 2011).”
BackgroundLiu, H., Dong, K., Zhang, W., Summerfield, S. G., & Terstappen, G. C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.03.002 · Cited by 74
Disdier, C., & Stonestreet, B. S. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24590 · Cited by 75
“Interplay of Drug Metabolizing CYP450 Enzymes and ABC Transporters in the Blood-Brain Barrier.”
BackgroundInfluentialMarkowicz-Piasecka, M., Markiewicz, A., Darłak, P., Sikora, J., Adla, S. K., Bagina, S., & Huttunen, K. M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01228-5 · Cited by 74
Chapy, H., Saubaméa, B., Tournier, N., Bourasset, F., Béhar‐Cohen, F., Declèves, X., Scherrmann, J., & Cisternino, S. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13376 · Cited by 73
“The ~2-fold higher P-gp expression measured at themouseBBB as comparedwith thehumanBBBbyproteomic studies may explain this discrepancy in scaling data from rodents to humans (Shawahna et al., 2011; Uchida et al., 2011b).”
BackgroundSelf-citationPathophysiological implications of neurovascular P450 in brain disorders
Ghosh, C., Hossain, M. K., Solanki, J., Dadas, A., Marchi, N., & Janigro, D. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.004 · Cited by 71
Ball, K., Bouzom, F., Scherrmann, J., Walther, B., & Declèves, X. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9496-0 · Cited by 67
“These values can be scaled to whole-brain permeability by multiplying by the amount of microvessel membrane protein in the in vivoBBB (milligrams of protein per gram of brain), which has been measured using quantitative proteomic methods (98).”
MethodSelf-citationTransport Characteristics of Tramadol in the Blood–Brain Barrier
Kitamura, A., Higuchi, K., Okura, T., & Deguchi, Y. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24129 · Cited by 67
Brake, L. H. M. T., de Knegt, G. J., de Steenwinkel, J. E. M., van Dam, T. J. P., Burger, D. M., Rüssel, F. G. M., van Crevel, R., Koenderink, J. B., & Aarnoutse, R. E. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052438 · Cited by 72
Ball, K., Bouzom, F., Scherrmann, J., Walther, B., & Declèves, X. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23266 · Cited by 66
Self-citationHarwood, M. D., Achour, B., Neuhoff, S., Russell, M. R., Carlson, G., Warhurst, G., & Rostami‐Hodjegan, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067371 · Cited by 68
Tournier, N., Saba, W., Cisternino, S., Peyronneau, M., Damont, A., Goutal, S., Dubois, A., Dollé, F., Scherrmann, J., Valette, H., et al. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9514-2 · Cited by 66
Self-citationFigueira, I., Tavares, L., Jardim, C., Costa, I., Terrasso, A. P., Almeida, A. F., Govers, C., Mes, J. J., Gardner, R., Becker, J. D., et al. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1576-y · Cited by 69
“In fact, enzymes primarily associated with hepatic drug metabolism have been shown to exist in the brain, albeit at relatively low specific activities [41] and may influence cerebral availability of various compounds at the blood–brain interface [40, 42].”
Decoding neuroproteomics: integrating the genome, translatome and functional anatomy
Kitchen, R. R., Rozowsky, J. S., Gerstein, M. B., & Nairn, A. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3829 · Cited by 63
A-Subclass ATP-Binding Cassette Proteins in Brain Lipid Homeostasis and Neurodegeneration
Piehler, A. P., Özcürümez, M., & Kaminski, W. E. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00017 · Cited by 53
“…brain cells including neurons and brain endothelial cells (Ohtsuki et al., 2004; Broccardo et al., 2006; Kim et al., 2006; Warren et al., 2009; Shawahna et al., 2011), and other tissues outside the CNS including monocytes, macrophages, T-cells, thyroid gland, kidney, liver, thymus, heart,…”
BackgroundNyúl-Tóth, Á., Suciu, M., Molnár, J., Fazakas, C., Haskó, J., Herman, H., Farkas, A. E., Kaszaki, J., Hermenean, A., Wilhelm, I., et al. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00774.2015 · Cited by 57
“The carrier function of CECs mainly relies on solute-like carriers (SLC transporters), the most important of which are SLC2A1/ GLUT1 (glucose transporter 1), SLC7A5/LAT1 (L-type amino acid transporter 1), SLC16A1/MCT1 (monocarboxylate transporter 1), SLC1A3/EAAT1 (excitatory amino acid transporter 1), and SLC1A2/EAAT2…”
BackgroundBhatt, D. K., & Prasad, B. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.819 · Cited by 65
Balogh, L. M. (2013) · Journal of Proteomics & Bioinformatics · doi:10.4172/jpb.1000285 · Cited by 67
“6-fold more expressed than MDR1 and MRP4 is 10 times less abundant than MDR1 [41].”
BackgroundInfluential
Metadata
- Authors
- Shawahna, R., Uchida, Y., Declèves, X., Ohtsuki, S., Yousif, S., Dauchy, S., Jacob, A., Chassoux, F., Daumas-Duport, C., Couraud, P.-O., Terasaki, T., & Scherrmann, J.-M.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Tohoku University (JP)
- Centre Hospitalier Sainte-Anne (FR)
- Ste Anne Hospital, Paris, France
- Inserm (FR)
- Corresponding author
- Declèves, Xavier
- ORCID
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-07-08
- Volume
- 8
- Issue
- 4
- Pages
- 1332-1341
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2090945850
- Cited by
- 372
- References
- 48
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 23 · 2023: 19 · 2022: 27 · 2021: 26 · 2020: 31 · 2019: 20 · 2018: 30 · 2017: 29 · 2016: 29 · 2015: 35 · 2014: 27 · 2013: 32 · 2012: 24
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23790170)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- cerebral microvasculature, blood-brain barrier, solute carrier transporters, organic cation transporters, ABC transporters, drug-metabolizing enzymes, drug transporters, GLUT1, GLAST, GLT-1, MDR1/ABCB1, ABCA2, ABCA8, CYP1B1, CYP2U1, glutathione S-transferase, catechol-O-methyltransferase, glioma
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Brain, Chromatography, Liquid, Glutathione Transferase, Humans, Neoplasm Proteins, ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters, ATP Binding Cassette Transporter, Subfamily B, Member 1, Excitatory Amino Acid Transporter 1, Excitatory Amino Acid Transporter 2, Proteomics, Glutamate Plasma Membrane Transport Proteins, Glucose Transporter Type 1, Glutathione S-Transferase pi, Tandem Mass Spectrometry, Microvessels, Transcriptome, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.